The aerodigestive tract is susceptible to Th2-related immune response, with allergic rhinitis and asthma being the most common manifestations. Allergic rhinitis has a significant socioeconomic impact, affecting both the quality of life of patients and the cost of national healthcare systems. Specifically, allergens trigger an IgE-dependent reaction in sensitized patients, leading to the release of mast cells and subsequent inflammation. Eosinophils and basophils play a crucial role in nasal mucosa hypersensitivity, becoming irritated by specific allergens. Common symptoms include pruritus, nasal congestion, nasal secretions, sneezing, and lacrimation following antigen exposure. Currently, allergic rhinitis is categorized as mild, moderate, or severe based on symptom severity, and as intermittent or persistent based on symptom duration. H1-antihistamines and leukotriene antagonists can partially control symptoms but do not fully alleviate nasal congestion. Intranasal steroids are often the first-line treatment as they improve quality of life and can be used alongside antihistamines for enhanced results. However, the only definitive solution is immunotherapy (sublingual and subcutaneous), due to its ability to modify the natural progression of the disease, often leading to permanent relief.